1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6AB6DDAD9D98DF83A002585A100485B29
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/how-biopharma-medical-device-companies-pivoting-support-boom-telehealth-during-covid-19-pandemic-beyond
18
19
2034.201.18.139
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Business Operations Information Technology

How Biopharma & Medical Device Companies are Pivoting to Support the Boom in Telehealth During the COVID-19 Pandemic and Beyond

ID: CM-10


Features:

8 Info Graphics

9 Data Graphics

190+ Metrics

20 Narratives


Pages: 26


Published: 2020


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Telehealth paves the way for convenient, affordable and readily-accessible health services in even the remotest areas. These features have accelerated the use of telehealthcare during the COVID-19 outbreak, causing many biopharma and medical device organizations to pivot find ways to support these rapidly emerging telehealth channels.

However, biopharma manufacturers are struggling to develop coherent strategies, identify logical approaches and adopt novel tools to ensure that they can provide valuable telehealth support services for physicians and patients.

Best Practices, LLC undertook this benchmarking research to understand how biopharmaceutical and medical device companies have pivoted to support a world where telemedicine is emerging as a permanent healthcare delivery channel.

This report provides benchmarks around the impact of operational services delivered via telehealth channels, valuable telehealth services offered by various biopharma groups, key lessons learned in each operational / functional area during COVID-19, and telehealth change duration.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Medical Device; Health Care; Biotech; Consulting; Consumer Products; Clinical Research; Laboratories; Medical


Companies Profiled:
AbbVie; Alkermes; Ascensia; AstraZeneca; BioDelivery Sciences International; Inc.; B.Braun; Canopy Growth; Catalyst Pharma; Daiichi Sankyo; DBV Tehcnologies; Dendreon Pharmaceuticals LLC; DiaSorin; EHOB; Inc; eNeura Therapeutics; Frankel Advisory Group LLC; Galderma; Greenwich Biosciences; Johnson & Johnson; Merck; Novartis; Panacea Biotec; Pfizer; Piramal Group; Rigel Pharmaceuticals; Sanofi; Santen; Sivantos Pte. Ltd.; Stgilesmedical London & Berlin; Sumitovant BioPharma; UCB Pharma; ViiV Healthcare; Zydus Cadila

Study Snapshot

Best Practices, LLC engaged 36 leaders from 32 biopharma and medical device organizations in this research through a benchmarking survey. Ninety percent of the participants serve at the director-level and above.

Key topics covered in this report include:

  • Impact of Operational Services via Telehealth Channel
  • Telehealth Service Channels
  • Key Lessons Learned
  • Telehealth Change Duration


Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Telehealth channel attraction will continue its growth across all operational areas post COVID-19 pandemic: Patient Support and Medical Affairs will have prominent roles in patient education and clinical support, whereas Sales will be the first to try and offer services via telehealth channel. Health Outcomes plans to offer valuable tele-services in the clinical support space.

  • Pharma plans to evolve delivery of outcomes studies (88%), support aids (76%), education & program support for providers and patients (>60%) over the telehealth channel. Currently, 60% of industry sales leaders provide targeted support through the tele-channel.

Table of Contents

Sr. No.
Topic
Slide No.
I.
Overviewp. 3-5
Universe of Learningp. 4
Key Insightsp. 5
II.
Impact of Operational Services via Telehealth Channelp. 6-8
III.
Telehealth Service Channelsp. 9-17
IV.
Lessons Learnedp. 18-19
V.
Telehealth Change Durationp. 20-22
VI.
Participant Demographicsp. 23-25
VII.
About Best Practices, LLCp. 26

    List of Charts & Exhibits

    I. Impact of Operational Services via Telehealth Channel

    • Future prospects of various biopharma operational groups in offering valuable services in support of the rapidly emerging tele-health channel – Medical, Marketing, Market Research and Sales groups
    • Future prospects of various biopharma operational groups in offering valuable services in support of the rapidly emerging tele-health channel – Health Outcomes, Managed Markets, Clinical Operations and Patient Support groups

    II. Telehealth Service Channels

    • Medical Affairs services refitted or adjusted by benchmark companies to support healthcare services delivered over telehealth channels, in light of the COVID-19 pandemic
    • Medical Affairs support for telehealth channel
    • Sales services refitted or adjusted by benchmark companies to support healthcare services delivered over telehealth channels, in light of the COVID-19 pandemic
    • Sales support for telehealth channel
    • Market Research services refitted or adjusted by benchmark companies to support healthcare services delivered over telehealth channels, in light of the COVID-19 pandemic
    • Adaptions of various functions
    • Marketing services refitted or adjusted by benchmark companies to support healthcare services delivered over telehealth channels, in light of the COVID-19 pandemic
    • New services piloted or in planning by benchmark companies to support a world where tele-medicine becomes an ongoing healthcare delivery channel, in light of the COVID-19 pandemic

    III. Lessons Learned

    • Lessons learned in each operational area related to telehealth delivery channel during COVID-19

    IV. Telehealth Change Duration

    • Benchmark groups’ planned approach to supporting telemedicine services after the global pandemic is ove